Telix Pharmaceuticals Ltd. has announced that its prostate cancer imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has received marketing authorization from the Austrian Medicines and Medical Devices Agency $(BASG)$. This approval allows healthcare providers in Austria to utilize PSMA-PET imaging for detecting and localizing prostate-specific membrane antigen-positive lesions in adults with prostate cancer. The decision is based on comprehensive clinical data, including findings from the VISION trial. Illuccix will be distributed in Austria by THP Medical Products, enabling wider access to this advanced diagnostic tool in a country where prostate cancer is the most prevalent cancer among men.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。